Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-07-01
2008-07-01
Wehbe, Anne Marie (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093210, C424S093400, C424S184100, C435S455000, C435S320100
Reexamination Certificate
active
07393525
ABSTRACT:
A method for introducing and expressing genes in animal cells is disclosed comprising infecting said the animal cells with live invasive bacteria, wherein bacteria contain a eukaryotic expression cassette encoding said gene. The gene may encode, e.g., a vaccine antigen, an therapeutic agent, an immunoregulatory agent or a anti-sense RNA or a catalytic RNA.
REFERENCES:
patent: 4082561 (1978-04-01), Nakagawa et al.
patent: 4190454 (1980-02-01), Yamagisi et al.
patent: 4204875 (1980-05-01), Szalavitz
patent: 4670055 (1987-06-01), Koslowski
patent: 4842649 (1989-06-01), Heitzmann et al.
patent: 4888170 (1989-12-01), Curtiss, III
patent: 5032181 (1991-07-01), Chung
patent: 5284513 (1994-02-01), Cowan et al.
patent: 5340397 (1994-08-01), Brothers
patent: 5588990 (1996-12-01), Dongell
patent: 5626665 (1997-05-01), Barger et al.
patent: 5728209 (1998-03-01), Bury et al.
patent: 5785751 (1998-07-01), Bashlykov et al.
patent: 5788762 (1998-08-01), Barger et al.
patent: 5824538 (1998-10-01), Branstrom
patent: 5877159 (1999-03-01), Powell
patent: 6136088 (2000-10-01), Farrington
patent: 6150170 (2000-11-01), Powell et al.
patent: 2003/0162741 (2003-08-01), Ng et al.
patent: 2003/0180320 (2003-09-01), Darji et al.
patent: 1289817 (2001-04-01), None
patent: 0 211 543 (1987-02-01), None
patent: 0 441 071 (1991-08-01), None
patent: 2 564 482 (1985-11-01), None
patent: WO 98/48026 (1998-10-01), None
Shandhu et al., Human Gene Therapy, Critical Reviews in Biotechnology 1997 17: 307-326.
Gunzburg et al., Molecular Medicine Today, Virus vector design in gene therapy.Dec. 1995;1(9):410-7.
Verma et al., Gene therapy—promises, problems and prospects. Nature. Sep. 18, 1997;389(6648):239-42.
Chu et al., Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells. Hum Gene Ther. Jan. 1, 1999;10(1):25-36.
Anderson WF Human gene therapy. Nature. Apr. 30, 1998;392(6679 Suppl):25-30.
Lechardeur et al., Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer.Gene Ther. Apr. 1999;6(4):482-97.
Brown MD, Schatzlein AG, Uchegbu IF.Gene delivery with synthetic (non viral) carriers. Int J Pharm. Oct. 23, 2001;229(1-2):1-21.
Zabner et al., Cellular and molecular barriers to gene transfer by a cationic lipid.J Biol Chem. Aug. 11, 1995;270(32):18997-9007.
Scientific Considerations Related to Related to Developing Follw-On Protein Products, 2004, p. 1-12.
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 1995 p. 11.
Marshall E.Gene Therapy's Growin Pains, Science. 1995, 25:1050, 1052-5.
Goodman and Gilman's The Pharmacological Basis of Therapeutics. Ninth Edition McGraw-Hill 1996 pp. 77-101.
Ledley FD Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. Sep. 1995;6(9):1129-44.
Weiss et al., Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers Current Opinion in Biotechnology vol. 12, Issue 5 , Oct. 1, 2001, pp. 467-472.
Krusch et al., Listeria monocytogenes mediated CFTR transgene transfer to mammalian cells The Journal of Gene Medicine vol. 4, Issue 6 , pp. 655-667.
Yuhua et al., Oral cytokine gene therapy against murine tumor using attenuatedSalmonella typhimuriumInternational Journal of Cancer, vol. 94, Issue 3 , pp. 438-443.
Leonard et al., Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12-Associated Toxicity and Interferon- Production Blood, vol. 90 No. 7 (Oct. 1), 1997: pp. 2541-2548.
High et al.,IpaB ofShigella flexnericauses entry into epithelial cells and escape from the phagocytic vacuole.EMBO J. May 1992;11(5):1991-9.
Weiss et al., Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers.Curr Opin Biotechnol. Oct. 2001;12(5):467-72.
Bernardini ML,et al., Identification of icsA, a plasmid locus ofShigella flexnerithat governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci U S A. May 1989;86(10):3867-71.
Eck & Wilson, ‘Gene-Based Therapy’ in Goodman & Gilmans' The Pharmacological Basis of Therapeutics, McGraw-Hill: New York, Ninth Edition, pp. 77-101 (1996).
Marshall et al,Science, 269:1050-1055 (1995).
NIH, “Report and Recommendations . . . ”, pp. 1-40 (Dec. 7, 1995).
Sizemore et al, “AttenuatedShigellaas a DNA Delivery Vehicles for DNA-Mediated Immunization,”Science, 270:299-302 (Oct. 13, 1995).
Slauch et al, “In Vivo Expression Technology for Selection of Bacterial Genes Specifically Induced in Host Tissues,”Methods in Enzymology, 235:481-492 (1994).
Cirillo et al, “Bacterial Vaccine Vectors and Bacillus Calmette-Guérin,”Clinical Infectious Diseases, 20:1001-1009 (1995).
Cardenas et al, “Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors,”Vaccine, 11(2):126-135 (1993).
Aggarwal et al, “OralSalmonella: Malaria Circumsporozoite Recombinants Induce Specific CD8+ Cytotoxic T Cells,”J. Exp. Med., 172(4):1083-1090 (Oct. 1990).
Noriega et al, “Construction and Characterization of Attenuated ΔaroA ΔvirGShigella flexneri2a Strain CVD 1203, a Protype Live Oral Vacine,”Infect. Immun., 62(11):5168-5172 (Nov. 1994).
Conry et al, “Characterization of a Messenger RNA Polynucleotide Vaccine Vector,”Cancer Res., 55:1397-1400 (Apr. 1, 1995).
Ulmer et al, “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein,”Science, 259:1745-1749 (Mar. 19, 1993).
Wolff et al, “Direct Gene Transfer into Mouse Muscle in Vivo,”Science, 247:1465-1468 (Mar. 23, 1990).
Gillies et al, “A Tissue-specific Transcription Enhancer Element is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene,”Cell, 33:717-728 (Jul. 1983).
Sandri-Goldin et al, “High-Frequency Transfer of Cloned Herpes Simplex Virus Type 1 Sequences to Mammalian Cells by Protoplast Fusion,”Mol. Cell. Biol., 1(8):743-752 (1981).
Schaffner et al, “Direct transfer of cloned genes from bacteria to mammalian cells,”Proc. Natl. Acad. Sci., USA, 77(4):2163-2167 (Apr. 1980).
Culver et al, “Gene Therapy for Cancer,”TIG, 10(5): 174-178 (May 1994).
Miller et al, “Targeted vectors for gene therapy,”FASEB J., 9:190-199 (Feb. 1995).
Rojanasakul, Y., “Antisense oligonucleotide therapeutics: drug delivery and targeting,”Adv. Drug Del. Rev., 18:115-131 (1996).
Fouts et al, “Construction and characterization of aSalmonella typhi-based human immunodeficiency virus type 1 vector vaccine,”Vaccine, 13(6):561-569 (1995).
Courvalian et al,Comples Rendus De L Academie Des Sciences: Series II: Sicences De La Terre et Des Planetes, 318(12):1207-1212 (1995).
Hodgson,Exp. Opin. Ther. Pat.., 5(5):459-468 (1995).
Hone David M.
Lewis George K.
Powell Robert J.
Leavitt Maria
Sughrue & Mion, PLLC
University of Maryland Baltimore
Wehbe Anne Marie
LandOfFree
Method for introducing and expressing genes in animal cells,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for introducing and expressing genes in animal cells,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for introducing and expressing genes in animal cells,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813312